Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia

Inclusion Criteria: 1. Patients ≥ 18 years old and ≤ 65 years old 2. Refractory/Relapse AML patients according to 2016 World Health Organization (WHO) classification; 3. Eastern Cooperative Oncology Group (ECOG) Performance status score less than 3; 4. Liver function: Total bilirubin ≦2 upper limit of normal (ULN); aspartate aminotransferase (AST) ≦3 ULN; alanine aminotransferase (ALT)≦3 ULN 5. Renal function：Ccr（Creatinine Clearance Rate） ≧30 ml/min; Scr (serum creatinine) ≦2 ULN 6. Heart function: left ventricular ejection fraction ≧45% 7. Patients must participate in this clinical trial voluntarily and sign an informed consent form. Exclusion Criteria: 1. Other diseases； 2. AML with central nervous system (CNS) infiltration； 3. Patients have received prior CAG or VA regimen before； 4. Patients with a life expectancy \<3 months 5. Patients with uncontrolled active infection; 6. HIV infection; 7. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to: a) Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. b) An active second cancer that requires treatment within 6 months of study entry 8. Female who are pregnant, breast feeding or childbearing potential. 9. Patients deemed unsuitable for enrollment by the investigator;